Potent suppressive effects of 3-O-methylquercetin 5,7,3′,4′-O- tetraacetate on ovalbumin-induced airway hyperresponsiveness

Planta Medica

Volumn 73, Issue 11, 2007, Pages 1156-1162

  Jiang, Jiunn Song ^a   Chien, Hui Chi ^b   Chen, Chien Ming ^b   Lin, Chun Nan ^c   Ko, Wun Chang ^b  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

3 o methylquercetin 5,7,3 ,4 o tetraacetate; Asthma; Cytokines; Inflammatory cells; Ovalbumin; Phosphodiesterase inhibitor

Indexed keywords

3 O METHYLQUERCETIN 5,7,3',4' O TETRAACETATE; ANTIASTHMATIC AGENT; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; METHACHOLINE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; QUERCETIN 3 O METHYL ETHER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AIRWAY HYPERRESPONSIVENESS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BINDING AFFINITY; BODY PLETHYSMOGRAPHY; BRONCHODILATING ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME INHIBITION; EOSINOPHIL; FEMALE; IC 50; INFLAMMATORY CELL; LYMPHOCYTE; MACROPHAGE; MALE; MAST CELL DEGRANULATION; NEUTROPHIL; NONHUMAN; RESPIRATORY TRACT DISEASE; TRACHEA MUSCLE;

ANIMALS; BRONCHIAL HYPERREACTIVITY; BRONCHODILATOR AGENTS; FEMALE; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; OVALBUMIN; PHYTOTHERAPY; PLANT EXTRACTS; QUERCETIN; RHAMNUS;

CAVIA; MUS;

EID: 35348836037     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-981587     Document Type: Article

References (30)

1. Lee ME, Markowitz J, Lee JO, Lee H. Crystal structure of phosphodiesterase 4D and inhibitor complex (1). FEBS Lett 2002; 530: 53-8.
2. de Boer J, Philpott AJ, van Amsterdam RG, Shahid M, Zaagsma J, Nicholson CD. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br J Pharmacol 1992; 106: 1028-34.
3. Silver PJ, Hamel LT, Perrone MH, Bentley RG, Bushover CR, Evans DB. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur J Pharmacol 1988; 150: 85-94.
4. Ko WC, Chen MC, Wang SH, Lai YH, Chen JH, Lin CN. 3- O-Methylquercetin more selectively inhibits phosphodiesterase subtype 3. Planta Med 2003; 69: 310-5.
5. Underwood DC, Kotzer CJ, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW et al. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther 1994; 270: 250-9.
6. Chiu NY, Chang KH. The illustrated medicinal plants of Taiwan. 5. Taipei: Southern Materials Center; 1998: 135-6.
7. Jiang JS, Shih CM, Wang SH, Chen TT, Lin CN, Ko WC. Mechanisms of suppression of nitric oxide production by 3-O-methylquercetin in RAW 264.7 cells. J Ethnopharmacol 2006; 103: 281-7.
8. Ko WC, Shih CM, Chen MC, Ui YH, Chen JH, Chen CM et al. Suppressive effects of 3-O-methylquercetin on ovalbumin-induced airway hyperresponsiveness. Planta Med 2004; 70: 1123-7.
9. Ferte J, Kuhnel JM, Chapuis G, Rolland Y, Lewin G, Schwaller MA. Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity, and structure-activity relationships. J Med Chem 1999; 42: 478-89.
10. Lin CN, Lu CM, Lin HC, Ko FN, Teng CM. Novel antiplatelet naphthalene from Rhamnus nakaharai. J Nat Prod 1995; 58: 1934-40.
11. Kanehiro A, Ikemura T, Makela MJ, Lahn M, Joetham A, Dakhama A et al. Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med 2001; 163: 173-84.
12. Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997; 156: 766-75.
13. Winterrowd GE, Chin JE. Flow cytometric detection of antigen-specific cytokine responses in lung T cells in a murine model of pulmonary inflammation. J Immunol Methods 1999; 226: 105-18.
14. Thompson WJ, Appleman MM. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 1971; 10: 311-6.
15. Ahn HS, Crim W, Romano M, Sybertz E, Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 1989; 38: 3331-9.
16. Podzuweit T, Nennstiel P, Muller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3- nonyl) adenine. Cell Signal 1995; 7: 733-8.
17. Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, Beavo JA. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol 1986; 29: 506-14.
18. Reeves ML, Leigh BK, England PJ. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem J 1987; 241: 535-41.
19. Gillespie PG, Beavo JA. Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948. Mol Pharmacol 1989; 36: 773-81.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
21. Tsien RW. Calcium channels in excitable cell membranes. Annu Rev Physiol 1983; 45: 341-58.
22. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001; 344: 350-62.
23. Revets H, Pynaert G, Grooten J, De Baetselier P. Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J Immunol 2005; 174: 1097-103.
24. Taube C, Duez C, Cui ZH, Takeda K, Rha YH, Park JW et al. The role of IL-13 in established allergic airway disease. J Immunol 2002; 169: 6482-9.
25. Tucker J, Fanta CH. Integrative inflammation pharmacology: asthma. In: Golan DE, Tashjian Jr AH, Armstrong EJ, Galanter JM, Armstrong AW, Arnaout RA et al., editors. Principles of pharmacology-the pathophysiologic basis of drug therapy Philadephia: Lippincott Williams & Wilkins; 2005: 695-705.
26. Vargaftig BB, Singer M. Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13. Am J Respir Cell Mol Biol 2003; 28: 410-9.
27. Murphy AW, Platts-Mills TAE. Drug used in asthma and obstructive lung disease. In: Brody TM, Larner J, Minneman KP, editors. Human pharmacology - molecular to clinical. St. Louis: Mosby; 1998: 797-825.
28. Groundwater PW, Solomons KR, Drewe JA, Munawar MA. Protein tyrosine kinase inhibitors. Prog Med Chem 1996; 33: 233-329.
29. Giembycz MA. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here? Drugs 2000; 59: 193-212.
30. Fan CK. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006; 533: 110-7.